Abciximab, ReoProÂ®, is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin ((alpha) v(beta)3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications.
in patients undergoing percutaneous coronary intervention
in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours
Safety and efficacy ofAbciximab use in patients not undergoing percutaneous coronary intervention have not beenestablished.
Abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in CLINICAL STUDIES.
Published Studies Related to Reopro (Abciximab)
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. [2011.06.01]
CONCLUSION: With limited assessment, this direct comparison of high-dose bolus tirofiban versus abciximab produced encouraging results and suggests that further study of this tirofiban dose regimen is warranted. The limited assessments comparing heparin and bivalirudin are consistent with prior observations. Copyright (c) 2010 Wiley-Liss, Inc.
Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI). [2011.05]
BACKGROUND: Administration of abciximab during primary percutaneous coronary intervention (PCI) reduces major adverse cardiac events (MACE) in patients with ST-elevation myocardial infarction (STEMI). Intracoronary (IC) abciximab bolus application during PCI results in high local drug concentration, improved perfusion, reduction of infarct size, and less microvascular obstruction early after infarction. Aim of this study was to investigate whether the early benefits of an IC abciximab administration in STEMI patients undergoing PCI are sustained at 6 months... CONCLUSIONS: Intracoronary abciximab application in STEMI patients undergoing PCI is superior to standard IV treatment with respect to infarct size, recovery of LV function and reverse remodelling 6 months after infarction.
Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial. [2011.04]
BACKGROUND: Abciximab is beneficial in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). However, the optimal administration route of the initial bolus of abciximab, that is, intravenous (IV) versus intracoronary (IC), has been questioned. Preliminary studies suggest that IC-bolus is superior, probably due to high local concentration. In this study, we assess the short-term efficacy and safety of IC compared to IV bolus of abciximab in patients with STEMI during pPCI... CONCLUSION: IC administration of bolus abciximab in STEMI patients undergoing pPCI reduces 30-day mortality and TVR and tends to reduce MI, compared to IV-bolus. (c)2010, Wiley Periodicals, Inc.
Rationale and design of the INFUSE-AMI study: A 2 x 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. [2011.03]
BACKGROUND: Whether thrombus aspiration and local glycoprotein IIb/IIIa administration reduce infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) has not been established in multicenter studies.SUMMARY: INFUSE-AMI is testing the hypothesis that the intracoronary administration of an abciximab bolus with or without thrombus aspiration before stent implantation compared to no infusion with or without thrombus aspiration reduces infarct size among patients undergoing primary PCI for anterior STEMI who are treated with bivalirudin.
Abciximab does not prevent ischemic lesions related to cerebral angiography: a randomized placebo-controlled trial. 
BACKGROUND: To assess the efficiency of IIb/IIIa platelet receptor inhibition by abciximab in the prevention of silent embolism during digital subtraction angiography... CONCLUSIONS: IIb/IIIa receptor inhibition by abciximab does not diminish the occurrence of silent embolism during digital subtraction angiography. Our findings indicate that solid blood clots are not the origin of hyperintense lesions observed on DWI and enhance the role of alternative mechanisms. Copyright (c) 2011 S. Karger AG, Basel.
Clinical Trials Related to Reopro (Abciximab)
Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis [Withdrawn]
The purpose of this study is to determine whether giving abciximab (ReoPro) to children with
sickle cell disease who are hospitalized for acute pain crisis will improve their pain and
shorten the time spent in the hospital, when compared with standard supportive care.
A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function [Active, not recruiting]
Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients
suffering an acute myocardial infarction.
The investigators hypothesise that treatment with intracoronary abciximab, a potent anti
platelet agent, at the time of coronary stent insertion, will improve microvascular
Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction [Completed]
The ADMIRAL (Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute
myocardial infarction) study demonstrated that early administration of abciximab in patients
with ST elevation acute myocardial infarction prior to PCI improves clinical outcomes but no
specifically designed randomized study has addressed the issue of early upstream use of GP
IIb/IIIa inhibitors in ST elevation acute myocardial infarction who are undergoing PCI,
especially in the era of routine pretreatment with 600 mg of clopidogrel. Therefore, the
objective of the randomized ECLAT-STEMI study was to assess the hypothesis that the early
upstream use of Clotinab is a useful therapy in patients with ST elevation MI undergoing PCI
compared to "provisional use", even after pretreatment with a 600-mg loading dose of
Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO) [Active, not recruiting]
The primary objective of this study is to investigate whether intracoronary bolus
administration of abciximab is superior to intravenous bolus administration in improving
myocardial perfusion in patients with ST-segment elevation myocardial infarction undergoing
primary percutaneous coronary intervention.
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty [Completed]
Reports of Suspected Reopro (Abciximab) Side Effects
Thrombosis in Device (7),
Incorrect Route of Drug Administration (6),
Myocardial Infarction (6),
Pulmonary Haemorrhage (6),
Cerebral Haemorrhage (5),
Haemorrhage Intracranial (5),
Renal Failure (5), more >>
Page last updated: 2011-12-09